Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, at 11:00 a.m. EDT at The Boston Marriott Copley Place. Mr. Auerbach will provide a company overview and update on the status of Cougar�s current clinical development programs.

Interested investors may access a live audio webcast by visiting the Investor Relations section of the Company�s Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being studied in a Phase III clinical trial in prostate cancer and a Phase I/II trial in breast cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar can be found at www.cougarbiotechnology.com.

Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Cougar Biotechnology (MM) Charts.
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Cougar Biotechnology (MM) Charts.